ClinicalTrials.gg
RecruitingNCT06520969Updated Nov 18, 2026

Prevelance of Uterine Vein and Uterine Vein System Variations

An interventional study of Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study) in Uterine Vein Injury Left and Uterine Vein Injury Right, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2024, registered Jul 2024).
  • Started Mar 2024; still recruiting 2 years 7 months later.
Updated Nov 18, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Sex
Female
01

Study summary

Contrary to the uterine arterial system, our knowledge about superficial and deep uterine vein prevalence and anatomic variations are limited. The present study aims to deepen and clarify our knowledge on superficial and deep uterine vein anatomy, prevalence and relationship with other neighbouring structures which may be helpful in uterine transplantation and radical hysterectomy operations.

Read the detailed description

Despite that two veins draining the uterus, superficial and deep, are described, their true anatomy, number, calibers, trajectories, relationships with sympathetic and parasympathetic nerves and internal iliac vasculature and ureters are quite limited. Additionally, variations of these vasculature are much less described. The aim of this study is to increase the our current knowledge about these anatomical information and also to calculate the prevalence of superficial and deep uterine veins which may potentially decrease the possible complications such as bleeding in uterine transplantation surgery and nerve sparing radical hysterectomy for cervical cancer.

02

Conditions studied

  • Uterine Vein Injury Left
  • Uterine Vein Injury Right
03

In context

Lead sponsor

Istanbul University is the lead sponsor of 514 studies on the registry; 78 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Endometrium and cervical cancer patients that will be operated -

Exclusion criteria

Exclusion Criteria:

Any women in whom uterine vascular anatomy that might be changed for a specific disease such as myomas, uterine infections, etc.

-

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    prevalance and anatomical variations of superficial and deep veins

    Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients

    Other: Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)

Interventions

  • OtherPrevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)

    Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients

    Also known as: Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients

06

What researchers measure

Primary outcomes

  1. To describe the prevalence of uterine vein and uterine vein system variations

    To describe the prevalence of uterine vein and uterine vein system variations

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all information stated in this document is open to to third parties whitout any limitations

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: no time frame limit, all open for all times

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2026 → Dec 2026 and completion Mar 2027 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2024
First posted
Jul 25, 2024
StartActual
Mar 30, 2024
Primary completionEst.
Dec 2026was Mar 2026
CompletionEst.
Dec 2026was Mar 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 30, 2026→Dec 2026
Nov 18, 2026
Study completion
Mar 30, 2027→Dec 2026
Nov 18, 2026
Enrollment
100→50
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Mar 30, 2026→Dec 2026
    Study completion Mar 30, 2027→Dec 2026
    Enrollment 100→50
    + 3 other changes: verification date, criteria formatting and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06520969
Responsible party
Mustafa Albayrak (MD, Gynecologic Oncology Fellow, Istanbul University) — Principal investigator
First posted
Jul 25, 2024
Start date
Mar 30, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Mustafa ALBAYRAK, MD
Contact
mustafaalbayrak@icloud.com
+90 532 687 10 51
Atahan TOYRAN, MD
Contact
atahantoyran@hotmail.com
+90 505 714 62 33
Samet Topuz, MD
study director · Istanbul Univrsity

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion